Fecal Microbiota Transplantation for the Prevention of Infectious Complications After Liver Transplantation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

The increasing emergence and spread of MDRB represents a major public health problem, with higher mortality in patients experiencing infections. Cirrhotic patients listed for OLT and after OLT are at high risk of MDRB colonization or infection due to the large use of broad-spectrum antibiotics in the post-transplant setting. Therefore, effective decolonization strategies in this particular setting are urgently needed. The investigators hypothesize that heterologous FMT can reduce infections rates in the pre-and post- OLT setting by MDRB decolonization and restoration of a more physiological microbiome.

Eligibility criteria

Qualifiers

Adult (age≥18 years) patients listed for OLT for various etiologies.

Patient's consent to participate in the study

Disqualifiers

Previous total colectomy

Pregnancy or breastfeeding

Patients on oral or intravenous antimicrobial agents

HIV positive and not well controlled on antiretroviral therapy, or CD4+ <200/ mm3

Trial design

Treatments tested in this trial

  • Fecal microbiota transplantation (FMT)

Treatment groups

144 Participants
are divided into 2 treatment groups